C. Difficile Infection Video Perspectives

Allegretti reports serving as a consultant for Abbvie, Adiso, Bristol Myer Squibb, Ferring, Finch Therapeutics, Iterative Scopes, Janssen, Merck, Pfizer, and Seres Therapeutics; as a speaker for Abbvie, BMS, and Janssen; and has received research support from Merck and Pfizer.

May 01, 2023

1 min watch

Save

VIDEO: Questions patients may have about C. difficile treatment

Transcript

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I’ve been doing FMT for a long time, and I think there were a lot of questions that I was getting maybe 10 years ago that I’m not getting anymore. I think patients want therapies like this. Of course, the success rates, I think, speak for themselves, and so often, the questions I get now are on insurance coverage. Will this be covered? How will we pay for this? What the whole finances of this are, and depending on which therapy you are offering, the answer is different.

I think still too often, if we’re discussing FMT patients, not regularly, they may ask, do I need to provide my own donor? How does that work? The answer is no. We don’t do donor-derived FMT anymore, and so really, a lot of the questions are around access and cost right now.